Table 2 Adverse event costs of advanced gastric cancer patients treated with ECX or FOLFIRI per cycle per patient.

From: Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma

Grade 3 to 4

ECX (N)

FOLFIRI (N)

Cost for ECX ($)

Cost for FOLFIRI ($)

First-line

200

203

  

 nonhematologic

107

108

4.74

4.30

 hematologic

129

78

13.18

7.18

 total

—

—

17.92

11.48

Second-line

101

81

  

 nonhematologic

47

44

5.20

6.54

 hematologic

44

35

11.24

12.00

 total

—

—

16.44

18.54

  1. ECX, epirubicin, cisplatin, and capecitabine; FOLFIRI, fluorouracil, leucovorin, and irinotecan; N, number.